Want to see CLYM full AI Analyst Report?
CLYM Stock Chart & Stats
$9.16
-$0.15(-7.18%)
At close: 4:00 PM EST
$9.16
-$0.15(-7.18%)
Day’s Range― - ―
52-Week Range$1.35 - $14.42
Previous CloseN/A
Volume51.97K
Average Volume (3M)1.52M
Market Cap
$801.68M
Enterprise Value$765.33M
Total Cash (Recent Filing)$109.56M
Total Debt (Recent Filing)$479.00K
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 18, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding57,263,023
10 Day Avg. Volume1,857,585
30 Day Avg. Volume1,518,354
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.97
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.22K
Enterprise Value/Ebitda-14.53
Forecast
1Y Price Target
$21.56Price Target Upside135.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-0.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Debt / Solid Balance SheetVery low financial leverage materially reduces solvency and refinancing risk for a clinical-stage biotech. This gives management optionality to fund trials, negotiate partnerships, or time equity raises, supporting sustained R&D programs without heavy interest expense pressure.
Budoprutug Encouraging Early ITP DataEarly Phase 1b ITP results showing durable platelet responses and strong B-cell depletion in refractory patients signal clinical proof-of-concept. Positive safety and efficacy in a difficult population strengthen the asset’s path to pivotal trials and potential competitive positioning in B-cell driven autoimmune indications.
CLYM116 Modeling Supports Less-frequent DosingTranslational pharmacometrics and early single-dose safety data that support less-frequent dosing can be a durable clinical and commercial advantage versus first-generation anti-APRIL drugs. Global Phase 1 data and a planned Phase 2 in China build a stronger, broader clinical dossier for regulatory and market access discussions.
Bears Say
Pre-revenue With High Cash BurnSustained negative operating and free cash flow creates persistent funding requirements. Elevated cash burn in recent periods increases reliance on external capital, compresses runway without dilution, and forces trade-offs between advancing multiple programs and preserving capital over the medium term.
Financing-driven Dilution RiskLarge equity financings and pre-funded warrants materially expand share count and create overhang. While proceeds extend runway, recurring reliance on equity issuance erodes per-share economics and can constrain long-term shareholder returns until meaningful revenue or partner-funded milestones are achieved.
Equity Erosion & Negative ROEMaterially negative ROE and declining equity reflect persistent value dilution from losses. Until the company achieves sustainable positive margins or secures non-dilutive funding, continued erosion of shareholder equity limits capacity to generate returns and weakens long-term investor economics.
Climb Bio News
CLYM FAQ
What was Climb Bio, Inc.’s price range in the past 12 months?
Climb Bio, Inc. lowest stock price was $1.35 and its highest was $14.41 in the past 12 months.
What is Climb Bio, Inc.’s market cap?
Climb Bio, Inc.’s market cap is $801.68M.
When is Climb Bio, Inc.’s upcoming earnings report date?
Climb Bio, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 37 days.
How were Climb Bio, Inc.’s earnings last quarter?
Climb Bio, Inc. released its earnings results on May 07, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.088.
Is Climb Bio, Inc. overvalued?
According to Wall Street analysts Climb Bio, Inc.’s price is currently Undervalued.
Does Climb Bio, Inc. pay dividends?
Climb Bio, Inc. does not currently pay dividends.
What is Climb Bio, Inc.’s EPS estimate?
Climb Bio, Inc.’s EPS estimate is -0.21.
How many shares outstanding does Climb Bio, Inc. have?
Climb Bio, Inc. has 57,263,023 shares outstanding.
What happened to Climb Bio, Inc.’s price movement after its last earnings report?
Climb Bio, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went down -2.537%.
Which hedge fund is a major shareholder of Climb Bio, Inc.?
Currently, no hedge funds are holding shares in CLYM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Climb Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.56 (135.32% Upside)
$21.56 (135.32% Upside)
Blogger Sentiment
Bullish
CLYM Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 7.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
937.03%
12-Months-Change
Fundamentals
Return on Equity
-31.46%
Trailing 12-Months
Asset Growth
-24.09%
Trailing 12-Months
Company Description
Climb Bio, Inc.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
CLYM Stock 12 Month Forecast
Average Price Target
$21.56
▲(135.32% Upside)
Technical Analysis
Agenus
―
TuHURA Biosciences
―
Ovid Therapeutics
―
Cognition Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
20.16% Insiders
5.55% Mutual Funds
39.82% Other Institutional Investors
27.89% Public Companies and
Individual Investors